Ultragenyx Pharmaceutical And Baylor Research Institute Reach Settlement Agreement With Esjay Pharma To Resolve Patent Litigation Related To The Company’s DOJOLVI Oral Liquid; Esjay Granted Non-Exclusive License For Generic DOJOLVI From 2033

뉴스 본문을 불러오고 있어요.

Ultragenyx Pharmaceutical And Baylor Research Institute Reach Settlement Agreement With Esjay Pharma To Resolve Patent Litigation Related To The Company’s DOJOLVI Oral Liquid; Esjay Granted Non-Exclusive License For Generic DOJOLVI From 2033 | 웨이프 WAPE

Ultragenyx Pharmaceutical And Baylor Research Institute Reach Settlement Agreement With Esjay Pharma To Resolve Patent Litigation Related To The Company’s DOJOLVI Oral Liquid; Esjay Granted Non-Exclusive License For Generic DOJOLVI From 2033

기사 요약

관련 종목

댓글 —